WO2026062521 - METHODS AND COMPOUNDS FOR PROMOTING SURVIVAL OF PHOTORECEPTORS
National phase entry is expected:
Publication Number
WO/2026/062521
Publication Date
26.03.2026
International Application No.
PCT/IB2025/059319
International Filing Date
17.09.2025
Title **
[English]
METHODS AND COMPOUNDS FOR PROMOTING SURVIVAL OF PHOTORECEPTORS
[French]
PROCÉDÉS ET COMPOSÉS POUR FAVORISER LA SURVIE DE PHOTORÉCEPTEURS
Applicants **
INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL (IOB)
Inventors
SPIRIG, Stefan Erich
ROSKA, Botond Miklós
Priority Data
63/696,182
18.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5754 | |
| EPO | Filing, Examination, Granting | 66523 | |
| Japan | Filing, Examination, Granting | 4091 | |
| South Korea | Filing, Examination, Granting | 5679 | |
| USA | Filing, Examination, Granting | 20540 |
Total:
102,587
Contact Us
Abstract[English]
The disclosure relates to methods of treating photoreceptor disease and/or inhibiting degeneration or death of photoreceptors. The methods comprise administering to a subject in need thereof a therapeutically effective amount of an inhibitor of mitogen-activated protein kinase 11 (MAPK11), an inhibitor of casein kinase 1 (CK1), or combinations thereof. This disclosure also relates to certain inhibitors of MAPK11 or CK1 and to pharmaceutical compositions that contain such inhibitors.[French]
La divulgation concerne des méthodes de traitement d'une maladie de photorécepteurs et/ou d'inhibition de la dégénérescence ou de la mort de photorécepteurs. Les procédés consistent à administrer à un sujet qui en a besoin une quantité thérapeutiquement efficace d'un inhibiteur de protéine kinase 11 activée par mitogène (MAPK11), d'un inhibiteur de caséine kinase 1 (CK1), ou de combinaisons de ceux-ci. La présente divulgation concerne également certains inhibiteurs de MAPK11 ou CK1 et des compositions pharmaceutiques qui contiennent de tels inhibiteurs.